XPREZA 300MG TABLET

Form: Tablets

Pack Size: 14 TABLETS

Marketed by: NATCO PHARMA LTD (ONCOLOGY DIV)

MRP: ₹14248.13

NATCO PHARMA LTD (ONCOLOGY DIV): Xpreza 300MG Tablet, 14 tablets, salt azacitidine 300mg. NPPA has revised its MRP from Rs 20,625 to Rs 14,248.13 (31% lower) with effect from 09-11-2026; trade rate Rs 10,855.72. Group: hypomethylating agent (chemotherapy). Same salt is also supplied by Hetero, MSN. Handling/counselling: injection and tablet forms are not interchangeable; cytotoxic: handle and dispose of as hazardous waste. Schedule H - supply only to licensed buyers and dispense only on prescription.

Available at wholesale price for chemists, retailers and distributors on WholesaleChemist.